Education
About Us
Working with TipRanks
Follow Us
Clal Biotechnology Industries Ltd (IL:CBI)
:CBI
Total Valuation
Clal Biotech has a market cap or net worth of ₪47.21M. The enterprise value is 65.88M.
Market Cap₪47.21M
Enterprise Value65.88M
Share Statistics
Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding156,846,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Clal Biotech’s return on equity (ROE) is -1.70 and return on invested capital (ROIC) is -9.47%.
Return on Equity (ROE)-1.70
Return on Assets (ROA)-0.92
Return on Invested Capital (ROIC)-9.47%
Return on Capital Employed (ROCE)-0.13
Revenue Per Employee2.97K
Profits Per Employee-514.21K
Employee Count146
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clal Biotech is ―. Clal Biotech’s PEG ratio is -0.00855.
PE Ratio―
PS Ratio123.31
PB Ratio1.46
Price to Fair Value1.46
Price to FCF-8.24
Price to Operating Cash Flow-8.49
PEG Ratio-0.00855
Income Statement
In the last 12 months, Clal Biotech had revenue of 433.00K and earned -62.46M in profits. Earnings per share was -0.40.
Revenue433.00K
Gross Profit-183.00K
Operating Income-6.34M
Pretax Income-75.07M
Net Income-62.46M
EBITDA-6.34M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was -5.42M and capital expenditures 0.00, giving a free cash flow of -5.42M billion.
Operating Cash Flow-5.42M
Free Cash Flow-5.42M
Free Cash Flow per Share-0.03
Dividends & Yields
Clal Biotech pays an annual dividend of 22.372, resulting in a dividend yield of ―
Dividend Per Share22.372
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.73
52-Week Price Change-11.14%
50-Day Moving Average32.08
200-Day Moving Average32.29
Relative Strength Index (RSI)44.83
Average Volume (3m)153.57K
Important Dates
Clal Biotech upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Clal Biotech as a current ratio of 0.29, with Debt / Equity ratio of 78.41%
Current Ratio0.29
Quick Ratio0.29
Debt to Market Cap0.36
Net Debt to EBITDA-2.66
Interest Coverage Ratio-1.87
Taxes
In the past 12 months, Clal Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Clal Biotech EV to EBITDA ratio is -11.08, with an EV/FCF ratio of -10.85.
EV to Sales162.32
EV to EBITDA-11.08
EV to Free Cash Flow-10.85
EV to Operating Cash Flow-10.85
Balance Sheet
Clal Biotech has ₪1.61M in cash and marketable securities with ₪18.70M in debt, giving a net cash position of -₪17.10M billion.
Cash & Marketable Securities₪1.61M
Total Debt₪18.70M
Net Cash-₪17.10M
Net Cash Per Share-₪0.11
Tangible Book Value Per Share₪0.29
Margins
Gross margin is 0.00%, with operating margin of -1465.36%, and net profit margin of -14424.02%.
Gross Margin0.00%
Operating Margin-1465.36%
Pretax Margin-17338.11%
Net Profit Margin-14424.02%
EBITDA Margin-1465.36%
EBIT Margin-1530.72%
Analyst Forecast
The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―